Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin novel formulations in adults with sickle cell disease
PACTR202206488890527Phase 2Not yet recruiting
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in sickle cell disease (SCD) (4 arms), sponsored by Valeant Pharmaceuticals. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202206488890527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202206488890527.